Last updated: July 24, 2023
Sponsor: Washington University School of Medicine
Overall Status: Active - Recruiting
Phase
2
Condition
Primary Insulin Hypersecretion
Treatment
18F-Fluoro Dopa PET/MRI Imaging
Clinical Study ID
NCT05088798
201801029
All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients with confirmed hyperinsulinemic hypoglycemia, diagnosed by elevated insulinlevels during hypoglycemia and/or response to glucagon stimulation.
- Subjects who failed pharmacological therapy with diazoxide or octreotide.
- Subjects with signed informed consent by themselves or their parents or legalguardians.
- Patient's Endocrinologist has determined that the patient cannot be safely managedwith standard medical therapy (failed) and surgery is recommended to prevent futureepisodes of severe hypoglycemia and preserve brain function.
Exclusion
Exclusion Criteria:
- Any other major illness or condition that in the investigator's judgment willsubstantially increase the risk associated with the subject's participation in thisstudy.
- Patient must not have any contraindication to MRI as evaluated by a standardized MRIsafety questionnaire. If MRI is contraindicated, and patient meets inclusion criteriaand has no other contraindications study will be conducted in PET/CT scanner.
- Cases in which surgery will not be considered by parents or guardians.
Study Design
Total Participants: 100
Treatment Group(s): 1
Primary Treatment: 18F-Fluoro Dopa PET/MRI Imaging
Phase: 2
Study Start date:
September 10, 2020
Estimated Completion Date:
January 01, 2030
Study Description
Connect with a study center
Washington University
Saint Louis, Missouri 63110
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.